The purpose of this study was to systematically assess the prevalence, clinical consequences, and reporting of treatment-emergent hypophosphatemia within literature investigating IVI therapies marketed in the United States (US)
Authors
John Glaspy, Michelle Lim-Watson, Michael A Libre, Swagata Karkare, Nandini Hadker, Aleksandra Bajic-Lucas, William Strauss, Naomi Dahl
Journal
Therapeutics and Clinical Risk Management